Carbamazepine/valproic acid interaction in man and rhesus monkey

Area of Science:

• Pharmacology
• Neuroscience
• Clinical Pharmacy

Background:

• Carbamazepine (CBZ) is a widely used antiepileptic drug.
• Drug interactions can alter the efficacy and safety of antiepileptic therapies.
• Sodium valproate (VPA) is another common antiepileptic medication.

Purpose of the Study:

• To investigate the pharmacokinetic interaction between sodium valproate (VPA) and carbamazepine (CBZ) in epileptic patients.
• To assess the impact of VPA on CBZ and its active metabolite, carbamazepine-10,11-epoxide (CBZE) plasma concentrations and protein binding.

Main Methods:

• Seven epileptic patients on chronic CBZ therapy received VPA for one week.
• CBZ and CBZE levels were measured before and after VPA administration.
• Plasma protein binding of CBZ was studied in healthy volunteers and rhesus monkeys with co-administered VPA.

Main Results:

• VPA reduced steady-state CBZ levels by 3-59% in most patients.
• The ratio of CBZE to CBZ increased significantly (11-500%) in all patients.
• VPA altered CBZ plasma protein binding and decreased the clearance of free CBZ and CBZE in animal models.

Conclusions:

• Concomitant administration of VPA with CBZ can lead to significant reductions in CBZ levels and alterations in its metabolite profile.
• The interaction may involve decreased elimination clearance of CBZE and altered protein binding of CBZ.
• These findings highlight the importance of therapeutic drug monitoring when VPA and CBZ are used together.